Meet The Professors: Breast Cancer Edition, 2018


MTPBreast18

Discussion

Track 1: Case: A 44-year-old woman is diagnosed with ER/PR-negative, HER2-positive breast cancer (BC) 6 months after bilateral reduction mammoplasty (Dr DeFusco)
Track 2: Efficacy and tolerability of neratinib as extended adjuvant therapy
Track 3: APHINITY: A Phase III trial of pertuzumab in combination with trastuzumab and chemotherapy as adjuvant therapy for patients with operable HER2-positive primary BC
Track 4: Benefits and risks of adjuvant pertuzumab and extended adjuvant neratinib
Track 5: Clinical implications of the APHINITY trial on the use of neoadjuvant therapy
Track 6: Case: A 52-year-old woman with ER/PR-negative, HER2-positive, node-positive inflammatory BC (Dr Carcas)
Track 7: Choice of chemotherapy for HER2-positive, node-positive inflammatory BC
Track 8: Efficacy of neratinib with or without capecitabine in patients with HER2-positive BC and brain metastases
Track 9: Ongoing investigation of neratinib for patients with HER2-mutant BC
Track 10: Activity of T-DM1 as second-line therapy for patients with metastatic HER2-positive BC
Track 11: T-DM1-associated side effects
Track 12: Case: A 65-year-old woman with ER/PR-negative, HER2-positive, node-positive BC and metastases in the brain and bones (Dr Stebel)
Track 13: Perspective on removal of the primary tumor in patients with metastatic BC
Track 14: Therapeutic options for patients after disease progression on docetaxel/trastuzumab/pertuzumab and T-DM1
Track 15: Consideration of CDK4/6 inhibitors for ER-positive, HER2-positive metastatic BC
Track 16: Viewpoint on the use of neratinib after trastuzumab-based adjuvant therapy
Track 17: Indications for neratinib and management of neratinib-associated diarrhea
Track 18: Comparison of anthracycline versus nonanthracycline-based regimens for HER2-positive BC
Track 19: Case: A 59-year-old woman with a 12-mm ER-positive, HER2-negative, node-negative IDC and a 21-gene Recurrence Score® (RS) of 32 (Dr DeFusco)
Track 20: Use of genomic assays to guide adjuvant decision-making for patients with ER-positive, HER2-negative BC
Track 21: Case: A 58-year-old woman with a 4-cm ER/PR positive, HER2-negative, node-negative BC (Dr Carcas)
Track 22: Perspective on the ASCO guidelines against using genomic assays for patients with node-positive, HR-positive BC
Track 23: Use of adjuvant bisphosphonates
Track 24: EBCTCG: A meta-analysis of individual patient data from randomised trials on the use of adjuvant bisphosphonates for patients with BC
Track 25: Bisphosphonate-associated side effects
Track 26: MINDACT trial: Utility of the 70-gene assay in selecting patients with BC and 1 to 3 positive nodes for adjuvant chemotherapy
Track 27: Use of the 21-gene assay in premenopausal women with ER-positive early BC
Track 28: Adjuvant ovarian suppression in premenopausal women with ER-positive BC
Track 29: Case: A 46-year-old woman who underwent treatment for Stage IIA lobular carcinoma in 2003 presents with recurrent ER-positive BC and metastases to the ovary and bone (Dr Stebel)
Track 30: Selection of CDK4/6 inhibitors for postmenopausal patients with ER-positive metastatic BC
Track 31: Activity and tolerability of abemaciclib in women with HR-positive advanced BC
Track 32: Comparison of the CDK4/6 inhibitors abemaciclib, palbociclib and ribociclib
Track 33: Therapeutic options for patients with disease progression on CDK4/6 inhibitors and endocrine therapy
Track 34: Ongoing trials evaluating novel approaches for patients with disease progression on CDK4/6 inhibitors
Track 35: Case: A 54-year-old woman who underwent treatment for ER/PR-positive, HER2-negative, node-positive, mixed ductal and lobular carcinoma in 2011 presents 5 years later with metastases in the bone and lymph nodes (Dr DeFusco)
Track 36: Perspective on the use of the 21-gene RS for patients with ER-positive, HER2-negative BC in the neoadjuvant setting
Track 37: Approach to neoadjuvant therapy for patients with infiltrating lobular carcinomas
Track 38: Management of ER-positive metastatic BC with palbociclib/letrozole
Track 39: Tolerability and activity of CDK4/6 inhibitors in the central nervous system (CNS)
Track 40: Dosing and schedule of administration of CDK4/6 inhibitors
Track 41: ESR1 mutation analysis in patients with ER-positive metastatic BC
Track 42: Case: A 30-year-old woman with germline BRCA2-mutant, ER-positive, HER2-negative metastatic BC and disease progression on palbociclib/letrozole (Dr Carcas)
Track 43: Therapeutic options for patients after treatment with palbociclib/letrozole
Track 44: Choice of chemotherapy for patients with ER-positive, HER2-negative metastatic BC and a germline BRCA mutation
Track 45: Perspective on the use of maintenance after chemotherapy for patients with germline BRCA-mutant, ER-positive metastatic BC
Track 46: Design and eligibility for the Phase III OlympiAD trial of olaparib versus chemotherapy for patients with HER2-negative metastatic BC and germline BRCA mutations
Track 47: Efficacy and side-effect profile with olaparib on the OlympiAD study
Track 48: Emerging data with PARP inhibitors in development for BC
Track 49: Activity of PARP inhibitors in patients with non-BRCA DNA repair mutations
Track 50: Potential integration of PARP inhibitors into the treatment algorithm for patients with germline BRCA-mutant metastatic BC
Track 51: Indications for BRCA testing in patients with BC
Track 52: Ongoing trials of PARP inhibitors in combination with chemotherapy
Track 53: Case: A 67-year-old woman who undergoes a mastectomy for TNBC develops recurrent disease 3 months later at the site of reconstruction and in the axillary nodes (Dr Stebel)
Track 54: Use of PARP inhibitors for patients with TNBC and germline BRCA mutations
Track 55: Sequencing of therapy for patients with metastatic TNBC
Track 56: Management of TNBC with CNS metastases
Track 57: Clinical experience with immune checkpoint inhibitors for patients with metastatic TNBC
Track 58: Investigation of PARP inhibitors in combination with checkpoint inhibitors
 
FACULTY
 
Sara A Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology/Oncology
University of California, Los Angeles
Medical Director
Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, California
Co-Director
Santa Monica-UCLA Outpatient Oncology Practices
Santa Monica, California
 
George W Sledge Jr, MD
Professor of Medicine
Chief, Division of Oncology
Department of Medicine
Stanford University School of Medicine
Stanford, California
 
COMMUNITY ONCOLOGISTS
 
Lauren Carcas, MD
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida
 
Patricia A DeFusco, MD
Clinical Assistant Professor of Medicine
University of Connecticut School of Medicine
Director, Hartford Hospital Breast Program
Physician Leader
Hartford Healthcare Cancer Institute
Breast Disease Management Team
Hartford, Connecticut
 
Andrea Stebel, MD
Hematology/Oncology
California Oncology
Newport Beach, California
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida